None listed
Conditions
Interventions
None listed
Sponsors
Hallym University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age = 18 years old and holding Korean (nationality) at the time of Informed consent 2) Voluntarily signed the informed consent form However, WGS(whole genome sequencing) test will only conducted on individuals who have voluntarily singed a separated consent form. 3) Patients who are to initiate lazertinib as the first line treatment ? EGFR L858R or 19del mutation-positive stage IV NSCLC patients, ? or Patients with EGFR L858R or 19del mutation-positive NSCLC who relapsed to stage 4 after surgery and had no history of EGFR-TKI treatment (neoadjuvant/adjuvant chemotherapy/radiotherapy before/after surgery is allowed)
Exclusion criteria
Exclusion criteria: 1) Age < 18 years old 2) histologically or cytologically not confirmed NSCLC 3) No EGFR L858R or 19del mutation 4) Not receiving lazertinib as first-line treatment 5) No agreement to participate in this study 6) Anticipated subject unable to complete the research as determined by the PI and Sub-I. 7) Patients enrolled in other studies related to lazertinib (Duplicate enrollment in other studies involving lazertinib was not allowed.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR);Duration of Response (DoR);Disease Control Rate (DCR);Time to treatment discontinuation (TTD);intracranial Objective Response Rate (icORR);intracranial Duration of Response (icDoR);intracranial Disease Control Rate (icDCR);intracranial Progression Free Survival (icPFS);Time to First Subsequent Therapy (TFST);Time to 2nd Progression free survival (PFS2);Overall Survival (OS);1-Year, 2-Year, 3-Year survival rate;Quality of Life;Adverse Events | — |
Countries
Korea, Republic of
Contacts
Public ContactSeung Hun Jang
Hallym University Medical Center
Outcome results
None listed